Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, will be presented at the 2013 Annual Meeting of the American Association of Cancer Research in Washington, D.C. Presentations include:
Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis
